Vinay Puduvalli K MD

Vinay Puduvalli K MD
ProfessorCollege of
M410 Starling Loving Hall 320 W 10th Avenue Columbus OH 43210
Phone:(614) 366-8343Fax: (614) 366-5763
  • Translational Therapeutics

Research Description

Dr. Puduvalli's academic interests are directed towards patient oriented research in preclinical, translational and clinical studies. He has initiated a comprehensive effort to study epigenetic modulation of targeted therapies against malignant gliomas. A proposed project is based on preclinical rationale for synergistic interaction and will examine the clinical effects of combining bevacizumab and vorinostat in a unique Bayesian adaptive randomized “pick the winner” 2 arm phase II trial. Dr. Puduvalli's lab is focused on characterizing epigenetic changes of clinical relevance in gliomas and glioma stem cells (GSC) by identifying epigenetic changes in gliomas as follows- 1) Epigenetic characterization of GSC by determining key promoter level interactions of DNA methylation with the stemness genes that regulate their expression with the goal to identify epigenetic switches governing stem to differentiated states and identify novel therapeutic targets. 2) Characterizing chromatin modification and the role of HDAC in stemness and drug resistance in glioma stem cells. 3) drug development and translational studies in gliomas. These studies are aimed at providing new insights into epigenetics and drug resistance of gliomas.

Current Publications

  • Penas-Prado M, Hess KR, Fisch MJ, Lagrone LW, Groves MD, Levin VA, De Groot JF, Puduvalli VK, Colman H, Volas-Redd G, Giglio P, Conrad CA, Salacz ME, Floyd JD, Loghin ME, Hsu SH, Gonzalez J, Chang EL, Woo SY, Mahajan A, Aldape KD, Yung WK, Gilbert MR, on behalf of the MD Anderson Community Clinical Oncology Program and the Brain Tumor Trials CollaborativeRandomized phase II adjuvant factorial study of dose-dense temozolomide alone and in combination with isotretinoin, celecoxib, and/or thalidomide for glioblastoma.Neuro Oncol in press 9/19/2014
  • Thorne AH, Meisen WH, Russell L, Yoo JY, Bolyard CM, Lathia JD, Rich J, Puduvalli VK, Mao H, Yu J, Caligiuri MA, Tridandapani S, Kaur BRole of Cysteine-rich 61 Protein (CCN1) in Macrophage-mediated Oncolytic Herpes Simplex Virus Clearance.Mol Ther 22 1678-87 9/1/2014
  • Puduvalli VK, DeGroot JF, Hamza MA, Mandel JJ, Conrad CA, Gilbert MR, Yung WKSurvival outcome of early versus delayed bevacizumab treatment in patients with recurrent glioblastoma.J Neurooncol 119 135-40 8/1/2014
  • Anderson MD, Hamza MA, Hess KR, Puduvalli VKImplications of bevacizumab discontinuation in adults with recurrent glioblastoma.Neuro Oncol 16 823-8 6/1/2014
  • Theeler BJ, Ellezam B, Sadighi ZS, Mehta V, Tran MD, Adesina AM, Bruner JM, Puduvalli VKAdult pilocytic astrocytomas: clinical features and molecular analysis.Neuro Oncol 16 841-7 6/1/2014
  • Barney CL, Brown AP, Grosshans DR, McAleer MF, de Groot JF, Puduvalli V, Tucker SL, Crawford CN, Gilbert MR, Brown PD, Mahajan ATechnique, outcomes, and acute toxicities in adults treated with proton beam craniospinal irradiation.Neuro Oncol 16 303-9 1/1/2014
  • Gopisetty G, Xu J, Sampath D, Colman H, Puduvalli VKEpigenetic regulation of CD133/PROM1 expression in glioma stem cells by Sp1/myc and promoter methylation.Oncogene 32 3119-29 6/27/2013

The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James) 460 W. 10th Avenue, Columbus, OH 43210 Phone: 1-800-293-5066 | Email: